2007
DOI: 10.1016/j.vaccine.2007.05.025
|View full text |Cite
|
Sign up to set email alerts
|

Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope

Abstract: The severe acute respiratory syndrome coronavirus nucleocapsid protein (SARS-CoV N) is one of the major targets for SARS vaccine due to its high potency in triggering immune responses. In this study, we have identified a novel HLA-A*0201 restricted epitope, N220 (LALLLLDRL), of the SARS-CoV N-protein through bioinformatics analysis. The N-protein peptide N220 shows a high binding affinity towards human MHC class I in T2-cells, and is capable of activating cytotoxic T-cells in human peripheral blood mononuclear… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
54
0

Year Published

2007
2007
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 47 publications
(58 citation statements)
references
References 36 publications
3
54
0
Order By: Relevance
“…Studies to date have used either H-2K b class I SCTs or HLA-A2 class I SCTs in the form of DNA vaccines to test the efficacy of SCTs in priming CD8 ϩ T cell responses in vivo in mouse models (5)(6)(7)(8)(9). In this study, we describe the properties of an SCT containing the H-2D b H chain and presenting a well-characterized epitope derived from influenza virus nucleoprotein (NP), residues 366 -374.…”
Section: T Here Is Continued Interest In Improving the Methods Availamentioning
confidence: 99%
See 1 more Smart Citation
“…Studies to date have used either H-2K b class I SCTs or HLA-A2 class I SCTs in the form of DNA vaccines to test the efficacy of SCTs in priming CD8 ϩ T cell responses in vivo in mouse models (5)(6)(7)(8)(9). In this study, we describe the properties of an SCT containing the H-2D b H chain and presenting a well-characterized epitope derived from influenza virus nucleoprotein (NP), residues 366 -374.…”
Section: T Here Is Continued Interest In Improving the Methods Availamentioning
confidence: 99%
“…Previous studies using MHC class I SCTs for priming in vivo have focused on using DNA vaccines (5)(6)(7)(8)(9). Although this approach has some advantages, the CD8 ϩ T cell responses generated are relatively weak, at least compared with the responses made against viruses.…”
Section: H-2d B Np Sct Primes a Vigorous Cd8 ϩ T Cell Response In Vivomentioning
confidence: 99%
“…Anti-inflammatory agents have also been used for clinical treatment (Fujii et al, 2004;Groneberg et al, 2005;Lai, 2005;So et al, 2003;Tsang and Seto, 2004;Tsang and Zhong, 2003;van Vonderen et al, 2003). SARS vaccines are currently under development and evaluation (Bai et al, 2008;Cheung et al, 2007;Groneberg et al, 2005;Jiang et al, 2005b;Lin et al, 2007;Marshall and Enserink, 2004;Martin et al, 2008;Okada et al, 2007;Oxford et al, 2005).…”
Section: Introductionmentioning
confidence: 99%
“…DNA vaccination of animal with SARS-CoV N gene led to the production of N-specific antibodies and specific cytotoxic T lymphocytes (CTLs) response, or even the replicon inhibition of vaccinia virus expressing N protein [21][22][23]. A DNA vaccine encoding N epitope stimulated cytotoxic T cells to kill N protein-expressing cell [24]. N protein expressed from recombinant measles and baculovirus resulted in strong humoral and cellular immune response in mice [25,26].…”
Section: Introductionmentioning
confidence: 99%